UCLA Scientists Develop Breakthrough Drug to Prevent Heart Failure After Heart Attacks
Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a new therapy that may improve heart repair after a heart attack. Cardiovascular disease is a leading cause of death globally, accounting for one-third of annual deaths. Following a heart attack, the heart has limited ability to heal, leading to scar tissue formation. This scar tissue can hinder the heart’s ability to pump blood, resulting in heart failure. Approximately 50% of patients with heart failure do not survive beyond five years, highlighting the urgent need for new treatments.
The therapy targets a protein called ENPP1, which contributes to inflammation and scar tissue formation after a heart injury. Researchers published their findings in Cell Reports Medicine. Arjun Deb, a professor at UCLA, led the study. He noted that options to improve heart healing have stagnated, with no specific medications available.
The experimental therapy uses a monoclonal antibody that blocks ENPP1. Deb’s team found that administering this antibody significantly improved heart repair in mice. Only 5% of treated mice developed severe heart failure after four weeks, compared to 52% in the control group.
This therapy may be the first to enhance heart healing directly after a heart attack. Current treatments mainly prevent further damage rather than promote recovery. The antibody approaches healing by targeting several cell types in the heart, including muscle cells and those that form blood vessels.
Interview with Arjun Deb, Professor at UCLA and Lead Researcher on Innovative Heart Therapy
News Directory 3: Thank you for joining us, Dr. Deb. Your team’s research on a novel therapy too improve heart repair after a heart attack is groundbreaking. Can you explain the meaning of ENPP1 and how your therapy interacts with this protein?
Arjun Deb: Thank you for having me. ENPP1 is a protein that plays a crucial role in promoting inflammation and the formation of scar tissue following heart injury.Our research suggests that by blocking ENPP1 with a monoclonal antibody, we can significantly reduce scar tissue, allowing the heart to heal more effectively after a heart attack.This is crucial because the current treatment options primarily focus on preventing further damage rather than promoting actual recovery.
News Directory 3: The statistics surrounding heart failure are alarming, with nearly 50% of patients not surviving beyond five years. How does your therapy aim to change these outcomes?
Arjun Deb: Yes, those statistics underline the urgent need for innovation in heart failure treatment. Our therapy has shown promising results in animal models, where we found that only 5% of treated mice developed severe heart failure compared to 52% in the control group. By enhancing heart repair directly after a heart attack, our approach may not only improve recovery rates but coudl also prolong survival in patients who experience heart failure.
News Directory 3: Can you elaborate on the mechanism through which your therapy facilitates heart healing?
arjun Deb: Certainly. The monoclonal antibody we are using targets multiple cell types in the heart, including cardiomyocytes, which are muscle cells, and endothelial cells, which are vital for blood vessel formation. By acting on these different cells, our therapy fosters a more favorable surroundings for healing and regeneration, thus minimizing scar formation.
News Directory 3: While your findings are promising,you mentioned the need for further research. What are your concerns about long-term effects, particularly regarding bone health?
Arjun Deb: That’s an critically important consideration. Inhibiting ENPP1 could have implications beyond the heart, including effects on bone health.We need to conduct more extensive studies to thoroughly understand these implications, so we can ensure the safety and efficacy of the therapy before it reaches the clinical trial stage.
News directory 3: You mentioned that your team is preparing to begin clinical trials.What is the timeline for this process?
Arjun Deb: We are planning to submit an investigational new drug application to the FDA this winter. This will set the stage for initiating human studies in early 2025, focusing on administering a single dose of the antibody to eligible patients shortly after a heart attack.
News Directory 3: Beyond cardiac applications, do you see potential for your therapy in treating other organs?
arjun Deb: Yes, one of our goals is to explore how this therapy can aid in the repair of other organs as well. The fundamental mechanisms involved in tissue repair across different organs are frequently enough quite similar, and thus, our approach may open the door to new treatments for various types of injuries.
News Directory 3: Thank you, Dr. Deb, for your time and insights. Your work could be a turning point in the treatment of heart injuries and potentially beyond.
Arjun Deb: I appreciate the possibility to share our research. We are hopeful about what’s to come and committed to advancing our findings for the benefit of patients.
Initial studies indicate that the therapy safely reduces scar tissue formation without increasing the risk of heart rupture. However, Deb cautioned that more research is necessary to understand the long-term effects of inhibiting ENPP1, particularly regarding bone health.
Deb’s team is preparing to start clinical trials. They plan to submit an investigational new drug (IND) application to the FDA this winter, aiming to begin human studies in early 2025. The studies will focus on giving a single dose of the drug to eligible patients soon after a heart attack.
Although the immediate focus is on heart repair, Deb’s team also aims to explore the therapy’s potential for healing other organs. Deb stated that the mechanisms for tissue repair are similar across different organs. This could lead to new treatments for various injuries.